Skye Bioscience, Inc. Increase (Decrease) in Accounts Payable, Related Parties
Skye Bioscience, Inc. (SKYE) reported Increase (Decrease) in Accounts Payable, Related Parties of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties · last filed 2025-03-20
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2024-12-31 was $0.00.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2024-09-30 was $0.00.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2024-03-31 was $0.00.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for fiscal 2024 was $0.00.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for fiscal 2023 was -$124.90K, a 212.05% decline from fiscal 2022.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for fiscal 2022 was $111.47K.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, related parties for fiscal 2021 was -$14.90K, a 311.92% decline from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Payable, Related Parties 3 month | Increase (Decrease) in Accounts Payable, Related Parties 6 month | Increase (Decrease) in Accounts Payable, Related Parties 9 month | Increase (Decrease) in Accounts Payable, Related Parties 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | -$11.30K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | -$11.30K derived: sum of 3 quarters · filed 2025-03-20 | -$108.30K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | -$11.30K derived: sum of 2 quarters · filed 2025-03-20 | -$108.30K derived: sum of 3 quarters · filed 2025-03-20 | -$104.57K derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | -$11.30K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$108.30K derived: sum of 2 quarters · filed 2025-03-20 | -$104.57K derived: sum of 3 quarters · filed 2025-03-20 | -$124.90K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$93.27K derived: sum of 2 quarters · filed 2024-11-07 | -$113.60K 10-Q · filed 2024-11-07 | -$120.22K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$16.60K 10-Q · filed 2024-08-09 | -$23.21K derived: sum of 3 quarters · filed 2024-08-09 | -$10.24K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$20.33K 10-Q · filed 2024-05-10 | -$26.95K derived: sum of 2 quarters · filed 2024-05-10 | -$13.97K derived: sum of 3 quarters · filed 2024-05-10 | $69.24K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$6.62K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $6.36K derived: sum of 2 quarters · filed 2024-03-22 | $89.58K derived: sum of 3 quarters · filed 2024-03-22 | $111.47K 10-K · filed 2024-03-22 |
| 2022-09-30 | $12.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $96.19K derived: sum of 2 quarters · filed 2023-11-14 | $118.09K 10-Q · filed 2023-11-14 | $100.22K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $83.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $105.11K 10-Q · filed 2023-08-07 | $87.24K derived: sum of 3 quarters · filed 2023-08-07 | $92.20K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $21.90K 10-Q · filed 2023-05-12 | $4.03K derived: sum of 2 quarters · filed 2023-05-12 | $8.99K derived: sum of 3 quarters · filed 2023-05-12 | $14.03K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$17.87K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$12.91K derived: sum of 2 quarters · filed 2023-03-31 | -$7.87K derived: sum of 3 quarters · filed 2023-03-31 | -$14.90K 10-K · filed 2023-03-31 |
| 2021-09-30 | $4.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $10.00K derived: sum of 2 quarters · filed 2022-11-14 | $2.97K 10-Q · filed 2022-11-14 | -$1.40K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $5.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.99K 10-Q · filed 2022-08-15 | -$6.36K derived: sum of 3 quarters · filed 2022-08-15 | -$62.25K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$7.03K 10-Q · filed 2022-05-06 | -$11.40K derived: sum of 2 quarters · filed 2022-05-06 | -$67.29K derived: sum of 3 quarters · filed 2022-05-06 | -$30.90K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | -$4.37K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$60.26K derived: sum of 2 quarters · filed 2022-03-28 | -$23.87K derived: sum of 3 quarters · filed 2022-03-28 | $7.03K 10-K · filed 2022-03-28 |
| 2020-09-30 | -$55.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$19.50K derived: sum of 2 quarters · filed 2021-11-10 | $11.40K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $36.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $67.29K 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $30.90K 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $10.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |